HIV risk behavior profiles among men who have sex with men interested in donating blood: Findings from the Assessing Donor Variability and New Concepts in Eligibility study
Corresponding Author
Brian Custer
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence
Brian Custer, Vitalant Research Institute, 360 Spear St, Suite 200, San Francisco, CA, 94105, USA.
Email: [email protected]
Search for more papers by this authorBarbee I. Whitaker
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorLance M. Pollack
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorRenata Buccheri
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorRoberta L. Bruhn
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorLauren A. Crowder
American Red Cross, Scientific Affairs, Rockville, Maryland, USA
Search for more papers by this authorSusan L. Stramer
American Red Cross, Scientific Affairs, Gaithersburg, Maryland, USA
Search for more papers by this authorSuchitra Pandey
Stanford Blood Center & Stanford University, Palo Alto, California, USA
Search for more papers by this authorMars Stone
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorClara Di Germanio
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorKate Buchacz
U.S. Centers for Disease Control and Prevention, HIV Research Branch, Division of HIV Prevention, Atlanta, Georgia, USA
Search for more papers by this authorAnne F. Eder
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorYun Lu
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorRichard A. Forshee
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorSteven A. Anderson
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorPeter W. Marks
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorCorresponding Author
Brian Custer
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence
Brian Custer, Vitalant Research Institute, 360 Spear St, Suite 200, San Francisco, CA, 94105, USA.
Email: [email protected]
Search for more papers by this authorBarbee I. Whitaker
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorLance M. Pollack
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorRenata Buccheri
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorRoberta L. Bruhn
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorLauren A. Crowder
American Red Cross, Scientific Affairs, Rockville, Maryland, USA
Search for more papers by this authorSusan L. Stramer
American Red Cross, Scientific Affairs, Gaithersburg, Maryland, USA
Search for more papers by this authorSuchitra Pandey
Stanford Blood Center & Stanford University, Palo Alto, California, USA
Search for more papers by this authorMars Stone
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorClara Di Germanio
Vitalant Research Institute, San Francisco, California, USA
Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorKate Buchacz
U.S. Centers for Disease Control and Prevention, HIV Research Branch, Division of HIV Prevention, Atlanta, Georgia, USA
Search for more papers by this authorAnne F. Eder
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorYun Lu
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorRichard A. Forshee
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorSteven A. Anderson
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorPeter W. Marks
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
Search for more papers by this authorThe views expressed in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Abstract
Background
Individual risk assessment allows donors to be evaluated based on their own behaviors. Study objectives were to assess human immunodeficiency virus (HIV) risk behaviors in men who have sex with men (MSM) and estimate the proportion of the study population who would not be deferred for higher risk HIV sexual behaviors.
Study Design and Methods
Cross-sectional survey and biomarker assessment were conducted in eight U.S. cities. Participants were sexually active MSM interested in blood donation aged 18–39 years, assigned male sex at birth. Participants completed surveys during two study visits to define eligibility, and self-reported sexual and HIV prevention behaviors. Blood was drawn at study visit 1 and tested for HIV and the presence of tenofovir, one of the drugs in oral HIV pre-exposure prophylaxis (PrEP). Associations were assessed between HIV infection status or HIV PrEP use and behaviors, including sex partners, new partners, and anal sex.
Results
A total of 1566 MSM completed the visit 1 questionnaire and blood draw and 1197 completed the visit 2 questionnaire. Among 1562 persons without HIV, 789 (50.4%) were not taking PrEP. Of those not taking PrEP, 66.2% reported one sexual partner or no anal sex and 69% reported no new sexual partners or no anal sex with a new partner in the past 3 months.
Conclusion
The study found that questions were able to identify sexually active, HIV-negative MSM who report lower risk sexual behaviors. About a quarter of enrolled study participants would be potentially eligible blood donors using individual risk assessment questions.
CONFLICT OF INTEREST STATEMENT
The authors have disclosed no conflicts of interest.
Supporting Information
| Filename | Description |
|---|---|
| trf17515-sup-0001-Supinfo.docxWord 2007 document , 49.4 KB | Data S1. Supporting information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Institute of Medicine, Committee to Study HIV Transmission Through Blood and Blood Products. In: LB Leveton, HC Sox, MA Stoto, editors. HIV and the blood supply: an analysis of crisis Decisionmaking. Washington, DC: National Academies Press (US); 1995.
- 2Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010; 50: 2080–2099.
- 3Custer B, Kessler D, Vahidnia F, Leparc G, Krysztof DE, Shaz B, et al. Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. Transfusion. 2015; 55: 1098–1107.
- 4Custer B, Sheon N, Siedle-Khan B, Pollack L, Spencer B, Bialkowski W, et al. Blood donor deferral for men who have sex with men: the blood donation rules opinion study (blood DROPS). Transfusion. 2015; 55: 2826–2834.
- 5Dodd RY, Notari EP, Nelson D, Foster GA, Krysztof DE, Kaidarova Z, et al. Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States. Transfusion. 2016; 56: 2781–2789.
- 6 U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products—guidance for industry. Silver Spring, MD: Food and Drug Administration; 2023 [accessed 2023 Feb 16]. Available from: https://www.federalregister.gov/d/2015-32250
- 7Grebe E, Busch MP, Notari EP, Bruhn R, Quiner C, Hindes D, et al. HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men. Blood. 2020; 136: 1359–1367.
- 8Steele WR, Dodd RY, Notari EP, Haynes J, Anderson SA, Williams AE, et al. HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion. 2021; 61: 839–850.
- 9 U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA provides updated guidance to address the urgent need for blood during the pandemic. Silver Spring, MD: Food and Drug Administration; 2020 [accessed 2020 Apr 9]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-updated-guidance-address-urgent-need-blood-during-pandemic
- 10Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005; 45: 254–264.
- 11 U.S. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2015–2019. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2023 [accessed 2023 Mar 23]. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
- 12Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. Aids. 2014; 28: 1509–1519.
- 13Baggaley RF, Owen BN, Silhol R, Elmes J, Anton P, McGowan I, et al. Does per-act HIV-1 transmission risk through anal sex vary by gender? An updated systematic review and meta-analysis. Am J Reprod Immunol. 2018; 80:e13039.
- 14Wang Y, Mitchell JW, Zhang C, Liu Y. Evidence and implication of interventions across various socioecological levels to address pre-exposure prophylaxis uptake and adherence among men who have sex with men in the United States: a systematic review. AIDS Res Ther. 2022; 19: 28.
- 15 Truvada® Package Insert. 2020 [accessed 2023 Ap 3]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/truvada/truvada_pi.pdf
- 16 Descovy® Package Insert. 2022 [accessed 2023 Apr 3]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/descovy/descovy_pi.pdf
- 17Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, et al. Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis. 2022; 225: 1741–1749.
- 18Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022; 175: 479–489.
- 19Custer B, Quiner C, Haaland R, Martin A, Stone M, Reik R, et al. HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. Blood. 2020; 136: 1351–1358.
- 20Harvala H, Reynolds C, Ijaz S, Maddox V, Penchala SD, Amara A, et al. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. Sex Transm Infect. 2022; 98: 132–135.
- 21Seed CR, Styles CE, Hoad VC, Yang H, Thomas MJ, Gosbell IB. Effect of HIV pre-exposure prophylaxis (PrEP) on detection of early infection and its impact on the appropriate post-PrEP deferral period. Vox Sang. 2021; 116: 379–387.
- 22 U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Recommendations for evaluating donor eligibility using individual risk-based questions to reduce the risk of human immunodeficiency virus transmission by blood and blood products, office of communication, outreach and development. Silver Spring, MD: Food and Drug Administration. 2023 [accessed 2023 Jun 8]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-evaluating-donor-eligibility-using-individual-risk-based-questions-reduce-risk-human
- 23Davison KL, Reynolds CA, Andrews N, Brailsford SR. Blood donation by men who have sex with men: using evidence to change policy. Vox Sang. 2021; 116: 260–272.
- 24Lambert G, Cox J, Fourmigue A, Dvorakova M, Apelian H, Moodie EEM, et al. HIV incidence and related risks among gay, bisexual, and other men who have sex with men in Montreal, Toronto, and Vancouver: informing blood donor selection criteria in Canada. Transfusion. 2022; 62: 2555–2567.
- 25 Canadian Blood Services. Sexual behaviour-based screening. 2023 [accessed 2023 Mar 14]. Available from: https://www.blood.ca/en/blood/am-i-eligible-donate-blood/sexual-behaviour-based-screening
- 26 U.K. National Health Service Blood and Transplant. Blood safety. 2023 [accessed 2023 Mar 14]. Available from: https://www.blood.co.uk/the-donation-process/further-information/your-safety/
- 27 U.S. Centers for Disease Control and Prevention. HIV infection risk, prevention, and testing behaviors among men who have sex with men—national HIV behavioral surveillance, 13 U.S. Cities, 2021. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2023 [accessed 2023 Mar 23]. Available from: https://www.cdc.gov/hiv/library/reports/hiv-surveillance-special-reports/no-31/index.html
- 28 Sedia Biosciences®. HIV-1 LAg-Avidity EIA. 2020 [accessed 2020 Feb 20]. Available from: http://www.sediabio.com/LiteratureRetrieve.aspx?ID=139682
- 29Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. Aids. 2019; 33: 701–708.
- 30Jones J, Pampati S, Emrick K, Siegler AJ. Demographic and behavioral characteristics of urban and non-urban PrEP-using MSM in the south. AIDS Care. 2022; 34: 1461–1464.
- 31Sullivan PS, Satcher Johnson A, Pembleton ES, Stephenson R, Justice AC, Althoff KN, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. Lancet. 2021; 397: 1095–1106.
- 32Pampati S, Emrick K, Siegler AJ, Jones J. Changes in sexual behavior, PrEP adherence, and access to sexual health services because of the COVID-19 pandemic among a cohort of PrEP-using MSM in the south. J Acquir Immune Defic Syndr. 2021; 87: 639–643.
- 33DiNenno EA, Delaney KP, Pitasi MA, MacGowan R, Miles G, Dailey A, et al. HIV testing before and during the COVID-19 pandemic—United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022; 71: 820–824.
- 34Chitwood MH, Kwon J, Savinkina A, Walker J, Bilinski A, Gonsalves G. Estimated testing, tracing, and vaccination targets for containment of the US Mpox outbreak. JAMA Netw Open. 2023; 6:e2250984.
Citing Literature
